Scientists from Brigham and Women's Hospital have successfully targeted the enzyme myosin light chain kinase 1 (MLCK1) to improve the symptoms of inflammatory bowel disease, while avoiding the toxicity that has doomed previous approaches. Read More
DBV Technologies SA, of Montrouge, France, said underwriters of its recent follow-on offering purchased 1.56 million American depositary shares of the company for $6.75 each, raising gross proceeds of the offering to about $81 million. Read More
The FDA issued a warning letter to Inova Genomics Laboratory, of Falls Church, Va., for illegally marketing certain genetic tests that have not been reviewed by the agency for safety and effectiveness. Read More
Precision Therapeutics Inc., of Minneapolis, completed its merger with Helomics Holding Corp., of Pittsburgh. The latter has become Precision's wholly owned subsidiary. Helomics is focused on women's oncology therapy that deploys the knowledge gained from the patient's own tumor using artificial intelligence technology. Read More
PERTH, Australia – Singapore-headquartered Cerecin Inc. is gearing up for a series of phase II trials in Australia of its lead compound, tricaprilin, for Alzheimer's disease. Read More
Advanced genome editing and synthetic biology have been used to bring to life a stripped down mathematical model of a yeast cell in which it is possible to finely tune G protein-coupled receptor (GPCR) signaling. Read More
LONDON – Nanobiotix SA has won European marketing approval for NBTXR-3, a first-in-class nanoparticle device that boosts the effectiveness of standard radiotherapy in killing cancer cells. The product, now christened Hensify, is a nanoparticle formulation of hafnium oxide, a material that absorbs X-rays, increasing the effective dose of radiation in a tumor. It is administered as a one-time injection into a tumor, given the day before conventional radiotherapy treatment. Read More
Initial data from the highest dose of the phase I/II Alta trial testing Sangamo Therapeutics Inc. and Pfizer Inc.'s SB-525 hemophilia A gene therapy look promising. Read More
HONG KONG – The biotech sector in greater China ended the financial year on a high note. Companies on the Hong Kong Stock Exchange reported better-than-expected results, including seven pre-revenue startups that went public over the last year, adding to the energy in the biotech space. Read More
Liquidia Technologies Inc. has announced additional positive safety and exploratory endpoint findings at the two-month timepoint in its phase III trial of LIQ-861, an inhalation dry powder formulation of treprostinil for patients with pulmonary arterial hypertension (PAH). Read More
During the American Association for Cancer Research (AACR) meeting in Atlanta recently, the FDA's Oncology Center of Excellence director, Richard Pazdur, called for more clinical teamwork among the makers of PD-1/PD-L1 inhibitors, and he's getting his wish – not from them but from Odonate Therapeutics Inc., developer of the oral taxane tesetaxel. Read More
